View all news

    DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma

    06/22/2021
    Download(opens in new window)PDF 241 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com